Status:
COMPLETED
Cytokines in Blister Fluids of Bullous Pemphigoid (BP)
Lead Sponsor:
Mahmut Can Koska
Conditions:
Pemphigoid, Bullous
Eligibility:
All Genders
18+ years
Brief Summary
This study investigates the differences of Eosinophil Cationic Protein, Tumor Necrosis Factor-alpha and Anti-BP180-NC16A IgG levels of blister fluids in Bullous Pemphigoid patients which appeared befo...
Detailed Description
Bullous Pemphigoid is an auto-immune bullous disorder in which auto-antibodies to hemidesmosomes, complement pathway, inflammatory cells and mediators play a crucial roles for disease pathogenesis. A...
Eligibility Criteria
Inclusion
- All patiens presented to clinics who is diagnosed with Bullous Pemphigoid by findings of clinical, histopathological, Direct Immunoflorescent evaluation.
- All relapsed/flared Bullous Pemphigoid patients.
- Patients who accept the terms and conditions and sign consent form.
Exclusion
- Patients who are received treatment before presenting clinics where the study is conducted.
- Patients who reject to join to study and the terms and condition
- Patients who leave the study by own decision
Key Trial Info
Start Date :
January 29 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 27 2019
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT03856840
Start Date
January 29 2018
End Date
August 27 2019
Last Update
October 4 2019
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Istanbul Medeniyet University Goztepe Training and Research Hospital
Istanbul, Kadikoy, Turkey (Türkiye), 37722
2
Istanbul Training and Research Hospital
Istanbul, Samatya, Turkey (Türkiye), 34098